Clinical Trial

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Study acronym: TulmiSTAR-01
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).
Protocol Amendment History 1 change
notable Trial sites expanded: 18 -> 25 locations 2026-04-02
Trial Details
NCT Number NCT07206056
Lead Sponsor Novartis Pharmaceuticals
Conditions Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment 188 participants
Start Date 2025-10-15
Primary Completion 2029-11-09 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-23